The joint venture, called Renx AI Labs, will allow RenalytixAI to operate outside New York City and perform prospective revenue-generating contract research.
Through the JV and strategic partnership, the companies aim to provide precision diagnostic products and services to Hong Kong, Macau, South Korea, and Southeast Asia.
The new firm, TaiRx US, is developing a drug and companion Dx for the nodal protein, which has been linked to aggressiveness and resistance in multiple cancers.
The JV, called ProMedica Pathology Laboratories, will combine the inpatient and outreach testing capabilities as well as esoteric testing capabilities of the partners.
